BlackRock’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,837,880
| Closed | -$94.6M | – | 5535 |
|
|
2024
Q3 | $94.6M | Buy |
2,837,880
+469,429
| +20% | +$16.2M | ﹤0.01% | 2121 |
|
|
2024
Q2 | $64M | Buy |
2,368,451
+502,161
| +27% | +$9.9M | ﹤0.01% | 2277 |
|
|
2024
Q1 | $40.3M | Buy |
1,866,290
+996,411
| +115% | +$21.7M | ﹤0.01% | 2571 |
|
|
2023
Q4 | $5.25M | Buy |
869,879
+84,043
| +11% | +$419K | ﹤0.01% | 3671 |
|
|
2023
Q3 | $4.37M | Buy |
785,836
+45,233
| +6% | +$291K | ﹤0.01% | 3705 |
|
|
2023
Q2 | $5.44M | Buy |
740,603
+711,581
| +2,452% | +$5.39M | ﹤0.01% | 3695 |
|
|
2023
Q1 | $116K | Buy |
29,022
+9,502
| +49% | +$46.4K | ﹤0.01% | 4926 |
|
|
2022
Q4 | $63.6K | Buy |
19,520
+623
| +3% | +$2.5K | ﹤0.01% | 5164 |
|
|
2022
Q3 | $70K | Sell |
18,897
-2,834
| -13% | -$10.5K | ﹤0.01% | 5283 |
|
|
2022
Q2 | $67K | Sell |
21,731
-8,938
| -29% | -$41.1K | ﹤0.01% | 5353 |
|
|
2022
Q1 | $164K | Buy |
30,669
+12,576
| +70% | +$59.6K | ﹤0.01% | 5161 |
|
|
2021
Q4 | $89K | Buy |
18,093
+470
| +3% | +$3.2K | ﹤0.01% | 5309 |
|
|
2021
Q3 | $156K | Sell |
17,623
-376
| -2% | -$3.47K | ﹤0.01% | 5039 |
|
|
2021
Q2 | $164K | Buy |
+17,999
| New | +$179K | ﹤0.01% | 4938 |
|
BlackRock's LBPH Position: Q4 2024 in Review
BlackRock sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 2,837,880 shares — an estimated $94.6M sold.
BlackRock first reported a position in LBPH in Q2 2021 and held it in 14 quarters. The position peaked at $94.6M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.
- BlackRock reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- BlackRock sold 2,837,880 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $94.6M.
- BlackRock first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q2 2021 and held it in 14 quarters.
- BlackRock's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $94.6M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on BlackRock's 13F filing for Q4 2024, filed 7 Feb 2025.